MDNAF (Medicenna Therapeutics) FCF Yield %: -46.32 (As of Jul. 01, 2026)


MDNAF Medicenna Therapeutics Corp MDNAF
29 GF Score
Price $0.30
! 1 Warning Sign
View Full Analysis

What is Medicenna Therapeutics FCF Yield %?

Medicenna Therapeutics MDNAF +9.49% 29 FCF Yield % is -46.32 as of Jul. 01, 2026. GuruFocus rates MDNAF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, Medicenna Therapeutics ranks worse than 83.17% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Medicenna Therapeutics's Trailing 12-Month Free Cash Flow is $-13.02 Mil, and Market Cap is $25.68 Mil. Therefore, Medicenna Therapeutics's FCF Yield % for today is -46.32%.

The historical rank and industry rank for Medicenna Therapeutics's FCF Yield % or its related term are showing as below:

MDNAF' s FCF Yield % Range Over the Past 10 Years
Min: -50.77   Med: 0   Max: 0
Current: -46.32

MDNAF's FCF Yield % is ranked worse than
83.17% of 1414 companies
in the Biotechnology industry
Industry Median: -9.46 vs MDNAF: -46.32

Medicenna Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

Medicenna Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Medicenna Therapeutics FCF Yield % Related Terms

Medicenna Therapeutics FCF Yield % Historical Data

* Premium members only.

The historical data trend for Medicenna Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics FCF Yield % Chart

Medicenna Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.16 -21.10 -12.59 -21.64 -34.04

Medicenna Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.17 -19.75 -24.12 -25.52 -34.00

MDNAF vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Medicenna Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicenna Therapeutics FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's FCF Yield % falls into.


MDNAF
29GF Score
Medicenna Therapeutics Corp MDNAF
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicenna Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Medicenna Therapeutics's FCF Yield % for the fiscal year that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-13.063 / 38.3715316
=-34.04%

Medicenna Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-3.262 * 4 / 38.3715316
=-34.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -46.32 mean?
Medicenna Therapeutics (MDNAF) has a FCF Yield % of -46.32 as of Jul. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Medicenna Therapeutics and its competitors. According to the industry distribution chart, Medicenna Therapeutics ranks #1176 out of 1414 companies in the Biotechnology industry, placing it in the top 83.2%.
Is Medicenna Therapeutics' FCF Yield % too high?
Medicenna Therapeutics' current FCF Yield % is -46.32. Based on the distribution chart, Medicenna Therapeutics ranks #1176 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medicenna Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medicenna Therapeutics ranks #1176 out of 1414 companies for FCF Yield %. This places Medicenna Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Medicenna Therapeutics and its competitors. Medicenna Therapeutics's current FCF Yield % is -46.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (MDNAF) has a current FCF Yield % of -46.32. The current FCF Yield % is -46.32. Medicenna Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Medicenna Therapeutics (MDNAF), the current FCF Yield % is -46.32 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicenna Therapeutics Business Description

Other Exchanges MDNA:Canada
Address 2 Bloor Street West, Suite 903, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
29GF Score

Get the complete analysis for MDNAF

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price